Cancervaccines review Peptide vaccination for cancer immunotherapy represents a promising strategy to harness the body's own immune system to recognize and attack malignant cellsPeptides as Versatile Regulators in Cancer Immunotherapy. These vaccines are designed based on specific epitope peptides, which are small fragments of proteins found on cancer cells. By presenting these peptides to the immune system, the goal is to elicit a robust and targeted immune response, particularly activating T cells, to eliminate tumor cells作者：Q Liu·2024·被引用次数：8—Further research and clinical trials are required tooptimize the application of peptide vaccines in cancer immunotherapyand improve patient clinical outcomes.. This approach offers a targeted method for cancer treatment, aiming to provide long-term acquired immunity with a comparatively low side-effect profile.A novel immunotherapeutic approach for advanced cancer
The development of peptide-based cancer vaccines is rooted in the understanding that the immune system, specifically cytotoxic T lymphocytes (CTLs), can be trained to identify and destroy cancer cells. Unlike some other cancer therapies, peptide vaccines aim to stimulate an endogenous immune response, utilizing the body's natural defenses. This method has shown great potential in cancer immunotherapy by targeting tumor antigens and activating the patient's immune system to fight the disease作者：AJ Stephens·2021·被引用次数：168—Peptide-based cancer vaccines rely upon the strong activation of the adaptive immune responseto elicit its effector function. They have shown to be highly ....
Peptide vaccines work by introducing specific peptide antigens that are derived from tumor-associated antigens (TAAs). These TAAs are proteins that are either overexpressed on cancer cells or are unique to them. When these peptides are administered, they are processed by antigen-presenting cells (APCs), which then present them to T cells. This presentation activates T cells, particularly CD8+ cytotoxic T lymphocytes (CTLs), which are crucial for killing cancer cells.
The process involves several key steps:
* Antigen Identification: Researchers identify specific peptides that are characteristic of cancer cells. These can be derived from known tumor antigens or from neoantigens, which are mutations unique to a patient's tumor.
* Vaccine Formulation: The selected peptides are synthesized and formulated into a vaccine.Peptide Vaccines in Cancer Immunotherapy This often involves combining them with adjuvants, substances that enhance the immune response, to ensure a strong and effective reaction.
* Immune Activation: Upon administration, the peptides are taken up by APCs. These APCs then migrate to lymph nodes, where they present the peptide antigens to T cells.
* T Cell Response: This presentation primes T cells to recognize and target cancer cells displaying the same peptide antigens.Adjuvants for peptide-based cancer vaccines The activated T cells then proliferate and travel to the tumor site to initiate an attack.
Significant progress has been made in the field of peptide vaccination, leading to its application in various cancer types and clinical trials. Personalized cancer vaccines, for instance, are being developed using neoantigen peptides specific to an individual's tumor. This personalized approach aims to maximize treatment efficacy by targeting the unique mutations present in a patient's cancer.
Synthetic long peptides (SLPs) are another area of advancement. These are longer peptide sequences that can more effectively mimic natural antigens and elicit stronger immune responsesAdvancements and Challenges in Peptide-Based Cancer Vaccination. They hold great promise as well-defined antigens for cancer immunotherapy.These peptides are engineered to elicit a specific immune responseby imitating certain epitopes from pathogens, like viruses, bacteria, or cancer cells. The ' ...
Research is also exploring composite peptide-based vaccines and liposome-based formulations to enhance the delivery and immunogenicity of peptide vaccines. These innovations aim to overcome some of the challenges associated with peptide vaccines, such as their immunogenicity and the potential for pre-existing immunity to vaccine peptides in some patientsVaccines to treat cancer.
Despite the considerable promise of peptide vaccination, challenges remain. Optimizing the application of peptide vaccines in cancer immunotherapy is crucial to improve patient clinical outcomes.作者：F Zahedipour·2023·被引用次数：27—Peptide vaccineshave shown great potential in cancer immunotherapyby targeting tumor antigens and activating the patient's immune system. This includes refining vaccine design, identifying the most immunogenic peptides, and developing strategies to overcome immune tolerance or pre-existing immunity to cancer antigens.Multi-disciplinary approaches paving the way for clinically ...
Further research and clinical trials are required to fully understand the mechanisms of action, improve efficacy, and establish peptide vaccines as a standard treatment option2016年5月26日—Synthetic long peptides (SLP) derived from cancer-associated antigenshold great promise as well-defined antigens for cancer immunotherapy.. The integration of peptide vaccines with other immunotherapeutic approaches, such as checkpoint inhibitors, is also an active area of investigation.作者：E Mizukoshi·2022·被引用次数：44—Peptide vaccines against cancer can augment tumor-specific T cell responses. Numerous peptides induce tumor-specific CD8+CTLs and tumor- ... The ultimate goal is to develop effective peptide vaccines that can provide durable anti-tumor immunity and improve long-term survival for cancer patients.
Join the newsletter to receive news, updates, new products and freebies in your inbox.